# scientific reports

Check for updates

## **OPEN** Learning curve for open surgical repair of acute type A aortic dissection

Bo-Cheng Hou<sup>1,6,7</sup>, Yu-Tung Huang<sup>3,7</sup>, Fu-Chih Hsiao<sup>2</sup>, Chien-Chia Wu<sup>4</sup>, Yu-Ting Cheng<sup>2</sup>, Kuo-Sheng Liu<sup>2,3</sup>, Shang-Hung Chang<sup>3,4</sup>, Pao-Hsien Chu<sup>4</sup>, An-Hsun Chou<sup>5</sup> & Shao-Wei Chen<sup>2,3</sup>⊠

There is scarce evidence about the surgeon learning curve of acute type A aortic dissection surgery and whether the optimal procedure number exists when training a cardiovascular surgeon. A total of 704 patients with acute type A aortic dissection surgery performed by 17 junior surgeons who can identify their first career surgery from January 1, 2005, to December 31, 2018, are included. The surgeon experience volume is defined as the cumulative number of acute type A aortic dissection surgery of the surgeon since January 1, 2005. The primary outcome was in-hospital mortality. The possibility of nonlinearity and cutoffs for surgeon experience volume level was explored using a restricted cubic spline model. The results revealed that more surgeon experience volume is significantly correlated to a lower in-hospital mortality rate (r = -0.58, P = 0.010). The RCS model shows for an operator who reaches 25 cumulative volumes of acute type A aortic dissection surgery, the average in-hospital mortality rate of the patients can be below 10%. Furthermore, the longer duration from the 1st to 25th operations of the surgeon is significantly correlated to a higher average in-hospital mortality rate of the patients (r=0.61, p=0.045). Acute type A aortic dissection surgery has a prominent learning curve in terms of improving clinical outcomes. The findings suggest fostering high-volume surgeons at high-volume hospitals can achieve optimal clinical outcomes.

Acute type A aortic dissection (ATAAD), the most lethal disease among acute aortic syndromes<sup>1</sup>, is an emergent condition and one of the most fatal diseases requiring immediate diagnosis and surgical intervention<sup>2</sup>. Although ATAAD is rare—with an incidence of 4 to 19 per 100 000 person-years<sup>3-5</sup>—its high mortality and rapid progression highlight the urgency for surgical intervention<sup>6,7</sup>. Surgical intervention has always been the optimal treatment for ATAAD<sup>8</sup>. A report based on the international registry of acute aortic dissection indicated that an increase in the trend of surgical management of ATAAD was correlated with a decrease in the mortality rate from 25% in the late 1990s to 18% in the 2010s<sup>9</sup>; this decrease is attributable to early detection, improved diagnostic methods, and advances in surgical techniques and postoperative care.

Despite advancements in knowledge and techniques regarding ATAAD treatment, in-hospital mortality has been prevalent, according to records from different populations and database<sup>3,4,10,11</sup>; this signifies the lethality of ATAAD pathogenesis and the need for a treatment technique with high proficiency and reliability<sup>12</sup>. ATAAD is an emergent disease with unpredictable characteristics. Accordingly, most patients with ATAAD may arrive at the emergency department unexpectedly and be operated on by an on-duty surgeon rather than an elective experienced surgeon<sup>13</sup>. Hence, a surgeon's proficiency and adaptability play crucial roles in such a challenging situation.

Several studies have explored the hospital volume-outcome relationship and surgeon total volume-outcome relationship for ATAAD surgical management<sup>11,14-16</sup> and have demonstrated favorable outcomes with increased

<sup>1</sup>Chiayi Branch, Chang Gung Memorial Hospital, No. 8, Sec. W., Jiapu Rd., Puzi City, Chiayi County, Taiwan. <sup>2</sup>Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Linkou Medical Center, Chang Gung Memorial Hospital, Chang Gung University, No. 5 Fuxing Street, Guishan District, Taoyuan City 33305, Taiwan. <sup>3</sup>Center for Big Data Analytics and Statistics, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan City, Taiwan. <sup>4</sup>Department of Cardiology, Linkou Medical Center, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan. <sup>5</sup>Department of Anesthesiology, Linkou Medical Center, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan. <sup>6</sup>Linkou Medical Center, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan. <sup>7</sup>These authors contributed equally: Bo-Cheng Hou and Yu-Tung Huang.<sup>™</sup>email: josephchen0314@gmail.com

volume. However, scarce evidence is available regarding the surgeon learning curve for surgical repair of ATAAD and the optimal operative volume (number of surgical procedures) exists for a cardiovascular surgeon under training. We hypothesized that accumulating surgical experience would be associated with improved surgical outcomes for ATAAD and that a precise operative volume exists for a surgeon to achieve consistently favorable surgical results. Accordingly, we retrospectively analyzed surgeons' sequential performance of ATAAD surgery and explored the optimal number of procedures (operative volume) required for a junior surgeon to achieve ideal surgical outcomes.

### Methods

**Data source.** Patient data were retrieved from the Chang Gung Research Database (CGRD). The CGRD includes detailed original medical records, such as laboratory reports, hemodynamic records, physical examination records, and medical imaging reports, from the Chang Gung Memorial Hospital system, which is composed of 3 tertiary medical centers and 4 regional medical institutions located from the northeast to southeast regions of Taiwan. Moreover, the CGRD covers 21.2% and 12.4% of the total national outpatient and inpatient visits, respectively<sup>17</sup>; it includes data on > 4 million outpatient visits, 200 000 emergency department visits, and 1 000 000 inpatient visits annually. This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (IRB No.: 202100124B0), and all methods in the article were performed in accordance with the guidelines and regulations of it. The need for informed consent was waived by the Institutional Review Board of Chang Gung Memorial Hospital.

**Study population.** Since the electronic records of CGRD initiated in 2001, patients with ATAAD who underwent open surgery due to an acute onset of aortic dissection between January 1, 2001, and December 31, 2018, were consecutively included. The presence of ATAAD and corresponding open surgery was ascertained through the examination of discharge diagnoses, operation notes, and discharge notes recorded in the CGRD subsets. These records were confirmed by 2 experienced cardiovascular surgeons. To evaluate the effect of the learning curve on perioperative outcomes, patients who were operated on by the surgeons (either senior or junior) who had surgical records between 2001 and 2004 were excluded from the main analysis (Fig. 1A). In other words, we only included patients whose surgeons started to operate since January 1, 2005. It's very unlikely that one surgeon conducted surgical repair of ATAAD before 2001 but did not conduct between 2001 and 2004. Therefore, to identify a surgeon's first career surgical repair of ATAAD, the learning curve was defined as the sequential number of open surgical procedures for ATAAD performed by the surgeon after January 1, 2005.

**Outcomes.** The primary outcome was in-hospital mortality, defined as death due to any reason during the index admission. The secondary outcomes comprised composite events (in-hospital mortality, new-onset stroke, new-onset hemodialysis, respiratory failure, use of extracorporeal membrane oxygenation, or massive blood transfusion [defined as packed red blood cell > 10 U]) during the index admission, bypass time, clamp time, and arrest time in surgery; length of intensive care unit (ICU) stay; and length of hospital stay. Information regarding the aforementioned outcomes was extracted from the death registry, inpatient claims data, operation notes, and discharge notes in the CGRD subsets.

**Covariates.** Covariates were age, sex, body weight, body height, body mass index, presenting complications (e.g. pain with radiation or chest pain or tightness), comorbid conditions (e.g. hypertension, coronary heart disease, end-stage renal disease, previous cardiac surgery history, or Marfan syndrome), severity of ATAAD (e.g. intramural hematoma, deBakey I, deBakey II), preoperative malperfusion syndrome, preoperative tamponade or shock, preoperative laboratory data (e.g. creatinine levels or whole blood cell count), postoperative laboratory data (e.g. platelet or hemoglobin levels), brain protection type, histidine-tryptophan-ketoglutarate solution volume, cerebral perfusion volume, and surgical extension for ATAAD (partial or total aortic arch replacement, aortic root replacement, elephant trunk, and ascending aorta replacement only). Information regarding the aforementioned covariates was extracted from the outpatient and inpatient claims data, laboratory records, computed tomography reports, operation notes, and discharge notes of the CGRD subsets.

**Statistical analysis.** First, surgeon operative volume is presented as a categorical variable stratified into 4 groups according to the sequential number of surgical procedures performed by surgeons: group 1 (comprising surgeries performed by surgeons' 1st to 10th volume), group 2 (comprising surgeries performed by surgeons' 11th to 20th volume), group 3 (comprising surgeries performed by surgeons' 21st to 30th volume), and group 4 (comprising surgeries performed by surgeons' > 30th volume). The linear trend of outcome across these groups was assessed using linear contrast analysis in a general linear model for continuous outcomes (i.e. clamp time) and the Cochran-Armitage trend test for categorical outcomes (i.e. in-hospital death). Due to the lack of normality, the linear trends of length of ICU stay and length of hospital stay across the ordinal groups of operative volume were evaluated using the nonparametric Jonckheere-Terpstra test.

Second, the relationship between surgeon operative volume (continuous variable) and the mean value of an outcome was assessed using Pearson's correlation. Only a few surgeons (n = 13) had performed > 20 operations at the time of the study. Therefore, surgeon operative volume was further stratified based on different strategies according to the sequential number of operations performed on patients: the first stratification comprised surgeons performing their 1st to 19th operations (the sequential numbers of operative volumes per dot: 2), second stratification comprised those performing their 20th to 39th operations (the sequential numbers of operative volumes per dot: 5), and third stratification comprised those performing their > 40th operations (the sequential numbers of operative volumes per dot: 10).



**Figure 1.** The flowchart for inclusion and exclusion of the study patients (**A**) and the relationship between cumulative operation volume of the surgeon (from 2001 to 2018) and the average in-hospital mortality rate of patients who are operated by the surgeon (**B**). Each point consists of all patients among the operations of the surgeon. Only those surgeons who conducted more than 10 operations are included in the plot. ATAAD, acute type A aortic dissection.

Since the choice of the cutoffs of the surgical volume above mentioned is arbitrary, we conducted an alternative model, of which the surgeon operative volume was treated as a restricted cubic spline (RCS) variable in the logistic regression model on in-hospital mortality. The possibility of nonlinearity and the potential cutoffs for optimal surgeon operative volume were explored in the RCS model. The number of knots was 4, and the locations were 5th, 35th, 65th, and 95th percentiles. Finally, the relationship between the duration from the 1st to 25th operations of the surgeon and in-hospital mortality rate was assessed using Pearson's correlation. RCS modeling was performed using R (version 4.0.2; R Foundation for Statistical Computing) and the RMS package (version 5.1-3.1; Frank E. Harrell Jr). Other statistical analyses were performed using SAS (version 9.4; SAS Institute, Cary, NC, USA). A 2-sided *P* value of < 0.05 was considered statistically significant.

#### Result

Of the 1102 patients with ATAAD who received open surgery (performed by 26 surgeons) between 2001 and 2018, 398 were excluded because they received surgery from senior surgeons (defined as surgeons who performed their first operation before January 1, 2005); we removed these patients to purify and clarify the learning curve for surgical repair of ATAAD, by precisely identifying a surgeon's first career ATAAD surgery. The remaining 704 patients (who received surgery from 17 junior surgeons) were selected in the analysis of surgeons' sequential performance of surgical repair of ATAAD (Fig. 1A).

For the 26 surgeons who were initially included from 2001 to 2018, the relationship between their total cumulative operative volumes and average in-hospital mortality rate of the patients who received their operations is illustrated in Fig. 1B. Only surgeons who had conducted > 10 operations were included in this analysis. The results revealed that a high cumulative operative volume was modestly correlated with a low in-hospital mortality rate (correlation coefficient [r] = -0.34), although the correlation was not significant (P=0.108). Furthermore, for the 17 remaining junior surgeons included from 2005 to 2018, detailed information regarding the cumulative operative volumes, in-hospital mortality, and composite events for patients is presented in Supplemental Table 1.

Among the remaining 704 patients, 153 were operated on by surgeons in group 1 (i.e. surgeons performing their 1st to 10th operations), 130 were operated on by those in group 2 (surgeons performing their 11th to 20th operations), 110 were operated on by those in group 3 (surgeons performing their 21st to 29th operations), and 331 were operated on by those in group 4 (surgeons performing their > 31st operations). The mean age and the proportion of male patients were 58 years and approximately 67% among all groups, respectively. The mean duration between the arrival time in the emergency department and the time entering the operation room was 1.8 h in average. For malperfusion syndrome, 35.5% patients had any aortic vascular branch involved, which did not demonstrate significant difference among groups. The majority of the patients presented with a chief concern of chest pain or back pain; 70.3% of the patients had a history of hypertension, 2.4% had Marfan syndrome, 1.7% had end stage renal disease receiving dialysis, and 1.56% received cardiac surgery previously. Regarding surgical procedures, 59.2% of the patients received surgery confined to the ascending aorta only, and 31.8, 6.7 and 3.3% of the patients received surgery that extended to the aortic arch, involved the Bentall procedure, and involved the frozen elephant trunk procedure, respectively. The differences in comorbidities and preoperative laboratory data across the 4 groups were nonsignificant (Table 1).

We treated surgeon operative volume as a categorical variable (Table 2). The results indicated that the inhospital mortality rate (*P* for trend = 0.031) exhibited a significant decreasing trend as the surgeon operative volume increased. We conducted the subgroup analysis by several variables, including any surgical extension, malperfusion syndrome, tamponade/shock, duration between the onset and entering the operating room, extent of dissection / severity, and aortic valve involvement (Table 2). The effect of surgeon operative volume was more pronounced in patients with any surgical extension (*P* for trend = 0.080), without malperfusion syndrome (*P* for trend = 0.056), with tamponade/shock (*P* for trend = 0.022), with longer duration between the onset and entering the operating room (*P* for trend < 0.001), with deBakey I (*P* for trend = 0.032) and without aortic valve involvement (*P* for trend = 0.022).

The results of secondary outcomes were shown in the supplements (Supplemental Table 2). The results indicated that composite events (*P* for trend = 0.016), and elongated arrest time during surgery (at cutoff of 60 min, *P* for trend = 0.005) exhibited a significant decreasing trend as the surgeon operative volume increased. The 4 groups did not differ significantly in terms of bypass time, clamp time, length of ICU stay, or length of hospital stay. We also considered different types of surgical procedures in this study. For procedures involving any extension from the ascending aorta, an elongated arrest time (*P* for trend = 0.001) exhibited a significant decreasing trend as the surgeon operative volume increased. For procedures that involved the ascending aorta only, composite events (*P* for trend = 0.029) and elongated clamp time (*P* for trend = 0.005) tended to be observed in the group with less operative volume.

Additionally, we treated surgeon operative volume as a continuous variable. Accordingly, a higher surgeon operative volume was significantly correlated with a lower in-hospital mortality rate (r = -0.58, P = 0.010; Fig. 2A), lower risk of composite events (r = -0.64, P = 0.003; Fig. 2B), and shorter length of ICU stay (r = -0.50, P = 0.029; Fig. 2D). However, surgeon operative volume did not exhibit a significant correlation with clamp time (r = -0.21, P = 0.385; Fig. 2C).

We also defined a satisfactory mortality rate for operations performed by a surgeon as an average in-hospital patient mortality rate of 10%. The RCS model revealed that the optimal volume of operations to be performed by a surgeon was 25. For a surgeon with an experience operative volume above 25 for ATAAD, the average inhospital mortality rate of the patients could be < 10% (Fig. 3A). Furthermore, the results showed that a longer duration from the 1st operation to the 25th operation by a surgeon was significantly correlated with a higher average in-hospital mortality rate of the patients (r=0.61, P=0.045; Fig. 3B). The relationship between the duration to the optimal operative volume and average in-hospital mortality rate was also linear in general (Fig. 3C).

#### Discussion

In this study, we examined the relationship between surgeon operative volume and the corresponding outcomes of surgical repair of ATAAD. We obtained 3 prominent findings. First, a prominent learning curve exists for surgical repair of ATAAD: experience accumulation was associated with improved patient outcomes and surgical safety. Second, a surgeon operative volume of >25 was related to an optimal in-hospital mortality rate, which was defined as  $\leq 10\%$ . Third, the duration to the optimal surgeon operative volume (25 operations) considerably influenced the patient outcomes, as a shorter duration was independently associated with more favorable surgical outcomes.

In general, ATAAD is a lethal cardiovascular disease<sup>18</sup>, with its reported in-hospital mortality rate ranging from 25 to 13%<sup>8,9,11,14,15</sup>. Due to its emergent and unpredictable nature<sup>19</sup>, numerous patients receive surgery performed by an on-duty surgeon under an emergent situation rather than under a well-scheduled setting. The chance of such surgery being performed by a junior surgeon, responsible for most duty work, is high. Hence, identifying the nature of the learning curve and implementing a relatively efficient training policy are crucial, This is particularly necessitated by the trend of a high proportion of patients receiving surgical repair rather than medication management in recent year<sup>9,20</sup>. Furthermore, surgery for ATAAD is a time-consuming process and

Namb				Number of ATAAD surgery of the surgeon						
DerespectiveSeries <th< td=""><td>Variable</td><td>Valid N</td><td>Total (N=704)</td><td><math>\leq</math> 10th (n = 153)</td><td>11th to 20th (n=130)</td><td>21th to 30th (n=110)</td><td>&gt; 30th (n = 311)</td></th<>	Variable	Valid N	Total (N=704)	$\leq$ 10th (n = 153)	11th to 20th (n=130)	21th to 30th (n=110)	> 30th (n = 311)			
AppsymbNo.<	Demographics									
MadeNameN	Age, year	704	58.4±13.7	$58.8 \pm 12.9$	$57.2 \pm 13.7$	$57.5 \pm 14.0$	59.1±14.1			
Body-spint, endorspint, <b< td=""><td>Male</td><td>704</td><td>473 (67.2)</td><td>103 (67.3)</td><td>92 (70.8)</td><td>75 (68.2)</td><td>203 (65.3)</td></b<>	Male	704	473 (67.2)	103 (67.3)	92 (70.8)	75 (68.2)	203 (65.3)			
Body log19741974 1219841984 121984 121944 121947 131944 12Protentig complication7771047710477104771047	Body weight, kg	704	73.1±16.3	73.5±16.0	75.2±18.7	70.3±14.0	72.9±16.0			
BML log/m2PAR-100 <td>Body height, cm</td> <td>704</td> <td>164.7±14.2</td> <td>163.9±14.8</td> <td>165.8±15.0</td> <td>164.3±15.5</td> <td>164.7±13.1</td>	Body height, cm	704	164.7±14.2	163.9±14.8	165.8±15.0	164.3±15.5	164.7±13.1			
PresentingProcession<	BMI, kg/m <sup>2</sup>	704	29.0±30.0	28.7±15.9	31.6±49.8	30.2±44.2	27.6±14.0			
Pain semigrationPain (Pain Pain Pain Pain Pain Pain Pain Pain	Presenting complications	I	l				<u> </u>			
Sheap eriginans[94[94030][940730][916730][916340][94030]Bak pair7441402011474025412016154036740Adominal pair7441403016240102401024026300Neck or head pair7441403017240754002130026300Depiperal indo weaks or mumbers7442130017240754002130021300Sprope744213016300764030973097Ohrac7442130213-3401912-29116150Diardon between the enrops of pair pair pair pair pair pair pair pair	Pain with radiation	704	77 (10.9)	23 (15.0)	13 (10.0)	14 (12.7)	27 (8.7)			
Back pain29414/2 (20.2)14/2 (20.4)14/2 (20.4)15/2 (20.4)15/2 (20.4)15/2 (20.4)Abdominpian20430 (21)14/2 (20)16.8)4(2.6)16.8)4(2.6)16.8)4(2.6)16.8)4(2.6)16.8)21.01Parighead lunks vakases ar anahores70424 (20)16.9030.9056.9050.9056.9050.90 <t< td=""><td>Chest pain or tightness</td><td>704</td><td>387 (55.0)</td><td>73 (47.7)</td><td>75 (57.7)</td><td>71 (64.6)</td><td>168 (54.0)</td></t<>	Chest pain or tightness	704	387 (55.0)	73 (47.7)	75 (57.7)	71 (64.6)	168 (54.0)			
Abdaminal pain764	Back pain	704	142 (20.2)	41 (26.8)	25 (19.2)	18 (16.4)	58 (18.7)			
NetworkangeTotoTotoTotoTotoTotoTotoTotoPeripheral limbs wakness or numbers74441.0011.027.64.021.0325.0351.0421.01Porpone74421.0215.98.020.15.47.64.080.0730.07Smoop of7472.10.2115.98.020.15.487.3020.0320.03Duration barven the one the thermal at hermory of86.809.59.07.63.087.3011.12.2.3111.12.2.3111.12.2.3111.12.2.3111.12.2.3111.12.2.3111.12.2.3111.12.2.3111.12.2.3111.12.2.3111.12.2.3111.13.111.12.2.3111.13.1	Abdominal pain	704	50 (7.1)	12 (7.8)	7 (5 4)	8(73)	23 (7 4)			
Name and and pointPart of the point of the po	Neck or head pain	704	14 (2.0)	4(26)	1 (0.8)	4(36)	5(16)			
AnymenAnymeA 2000A ConA ConA ConA ConSynope7042 (1026 (30)5 (30)5 (40)6 (31)Synope7047 (102)1 (80)7 (54)8 (102)3 (102)Daration batween the oner (the arrival at the emperingand1 (12-2)1 (12-2)1 (12-2)1 (12-2)1 (12-2)Adjertamen) and memering the operating non-miningand1 (12)1 (12)1 (12)1 (12)1 (12)Adjertamen Memering the operating non-mining7042 (15)1 (16)1 (	Perinheral limbs weakness or numbress	704	42 (6.0)	11 (7 2)	7 (5.4)	2 (1.8)	22 (7 1)			
Dynamic <t< td=""><td>Ducmen</td><td>704</td><td>22 (3.1)</td><td>6(3.9)</td><td>5 (3.9)</td><td>5 (4.6)</td><td>6 (1 9)</td></t<>	Ducmen	704	22 (3.1)	6(3.9)	5 (3.9)	5 (4.6)	6 (1 9)			
SynchreiNo.10.00.00 <td>Sumcono</td> <td>704</td> <td>72 (10.2)</td> <td>15 (0.8)</td> <td>3(3.5)</td> <td>7 (6 4)</td> <td>30 (0.7)</td>	Sumcono	704	72 (10.2)	15 (0.8)	3(3.5)	7 (6 4)	30 (0.7)			
During During method her many and the mengend apartime method her many and entering the operanting room, have apartimely and entering the operanting room, have apartimely and entering the operanting room, have by a la (12)-3335 (13)-0(13)-0(11	Others	704	72 (10.2)	13 (9.8)	20 (13.4)	7 (0.4) 8 (7.2)	30 (9.7)			
Jurnal network me over the arrow at the energy algebrane and actening the operating one, ins69018 [12-30]18 [13-34]19 [13-34]19 [12-29]18 [12-38]Majertinesi221033 <t< td=""><td></td><td>704</td><td>56 (8.0)</td><td>9 (5.9)</td><td>7 (5.4)</td><td>8 (7.3)</td><td>32 (10.3)</td></t<>		704	56 (8.0)	9 (5.9)	7 (5.4)	8 (7.3)	32 (10.3)			
MatrixCoronaryPM21.0.030.0.030.0.04.6.0.010.0.0.0Carcendr74064.0.064.0.00.0.0.010.6.0.0Righ carchal74084.0.010.6.0.010.0.0.028.0.0.0Calac trunk74097.0.010.8.0.05.0.0.03.0.0.03.0.0.0Left read74097.0.010.8.0.05.0.0.03.0.0.03.0.0.0Eight read74097.0.010.8.0.05.0.0.010.8.0.05.0.0.03.0.0.0Right read74097.0.08.0.0.06.0.0.010.8.0.05.0.0.03.0.0.03.0.0.0Right read74097.0.08.0.0.07.0.0.010.0.0.010.0.0.03.0.0.03.0.0.0Right read74097.0.097.0.07.0.0.010.0.0.010.0.0.010.0.0.010.0.0.0Any obsore74097.0.097.0.097.0.010.0.0.010.0.0.010.0.0.010.0.0.010.0.0.0Severity74097.0.010.0.010.0.	department) and entering the operating room, hrs	690	1.8 [1.2—3.35]	2.5 [1.5-4.9]	2 [1.3—3.4]	1.9 [1.2—2.9]	1.6 [1-2.8]			
Concern10101010101010Ichered74840140 </td <td>Malperfusion</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Malperfusion									
Internation74484.0474.49	Coronary	704	21 (3.0)	3 (2.0)	3 (2.3)	4 (3.6)	11 (3.5)			
Ngh cerebal744619.114.02.011.05.011.00.028.09.0Cala trunk74436.5.010.65.021.15.076.4.036.0.0Mesenteric74436.75.013.08.05.3.9.03.2.7.016.15.0Iafteral74466.02.016.01.012.02.015.13.6.031.00.0Righteral74466.02.016.05.012.63.021.63.021.63.0Right specific fill74446.10.08.62.06.5.021.68.0Aga base74447.67.09.59.07.54.054.64.026.63.0Aga base74220.55.07.64.03.64.04.60.7Severity74213.18.020.17.010.15.420.10.0Aga base74213.18.020.17.010.16.010.15.4Aga base74213.18.020.17.010.16.010.15.4Aga base74274.074.010.00.010.00.010.00.0Aga base74.074.074.074.074.074.0Aga base74.074.074.074.074.074.0Aga base74.074.074.074.074.074.0Aga base74.074.074.074.074.074.0Aga base74.074.074.074.074.074.0Aga base74.074.074.074.074.074.0Aga base74.074.074.074.0 <td< td=""><td>Left cerebral</td><td>704</td><td>32 (4.5)</td><td>7 (4.6)</td><td>6 (4.6)</td><td>0 (0.0)</td><td>19 (6.1)</td></td<>	Left cerebral	704	32 (4.5)	7 (4.6)	6 (4.6)	0 (0.0)	19 (6.1)			
Celia trunk7049(5.5)10 (6.5)2 (1.5)7 (6.4)20 (4.4)Mesentric70437 (.5.3)13 (.6.5)5 (.3.0)3 (.2.7)16 (.5.1)Left renal7048 (011.4)2 (1.5.7)15 (1.3.6)3 (1.0.0)Right renal7048 (0.1.4)8 (.5.2)8 (.2.0)6 (.5.5)2 (.6.5)Left lower limb7044 7 (.6.7)9 (.5.9)7 (.5.4)5 (.4.6)26 (.6.7)Apy of above7044 7 (.6.7)9 (.5.9)7 (.5.4)5 (.4.6)26 (.6.7)Severity7042 (.5.7)5 (.5.1)2 (.5.7)5 (.4.6)26 (.5.7)2 (.5.7)MH13 (1.8.9)2 (.7.7)2 (.5.9)2 (.5.9)2 (.5.9)2 (.7.7)2 (.5.9)deBakey I11.31.3 (.8.9)2 (.7.1)2 (.5.9)2 (.9.7)2 (.5.7)2 (.5.7)deBakey I11.31.3 (.8.9)2 (.7.1)2 (.5.9)2 (.9.7)2 (.5.7)2	Right cerebral	704	64 (9.1)	14 (9.2)	11 (8.5)	11 (10.0)	28 (9.0)			
Meenetric7047(5.3)13 (8.5)5(3.9)12 (2.7)15 (1.6)16 (1.6)Left real70480 (1.1)24 (15.7)10 (7.0)15 (1.8)31 (1.0)Right real70465 (9.2)16 (0.5)12 (9.2)13 (1.18)24 (7.5)Left lower limb70447 (6.7)9 (5.9)7 (5.4)5 (6.5)21 (6.8)Right over limb70447 (6.7)9 (5.9)7 (5.4)3 (8.4)3 (8.4)3 (8.4)Any of above704250 (35.5)9 (38.6)41 (3.1)3 (3.1)3 (3.4)3 (3.1)3 (3.4)Severity70270270320 (7.5)20 (9.5)3 (3.6)3 (3.1)3 (3.6)5 (3.6)Gebaky I60010.9(3.9)86 (72.2)20 (7.7)4 (6.8)3 (1.0)5 (1.6)Advita via involvement (actric valve involvement (actric	Celiac trunk	704	39 (5.5)	10 (6.5)	2 (1.5)	7 (6.4)	20 (6.4)			
Left renal70480(11.4)24(15.7)10(7.7)15(13.6)11(1.0)Right renal70465(9.2)16(10.5)12(9.2)15(11.6)24(7.7)Left lover limb70447(6.7)9(5.9)7(5.4)5(4.6)26(8.1)Any ofabove70420(35.5)59(38.6)43(3.1)38(34.6)10(35.1)Severity7027700102deBaky I13052(80.1)127(8.30)10(9.3)8(78.2)240(7.7)deBaky I770010.8)10.95(1.6)Arctic valve involvement (active valve replacement)7.452(8.0)10(7.7)11(0.0)5(1.6)Arctic valve involvement (active valve replacement)7.452(8.0)10(7.7)11(0.0)5(1.6)ComorbititieComorbititiesPrevious candicasargery74495(7.3)12(7.32)92(7.8)14(7.3)12(9.8)Coronary heart disease74495(7.3)12(7.3)12(7.3)12(9.1)11(9.1)12(9.8)Diabetes mellitus74495(7.3)12(7.3)12(7.3)12(9.1)12(9.8)12(9.1)Diabetes mellitus74495(7.5)15(1.5)15(1.5)15(1.5)15(1.5)15(1.5)Diabetes mellitus74491(7.1)14(1.4)14(1.4)14(1.5)14(1.4)14(1.4)14(1.5)14(1.5)13(1.6)14(1.6)Diabetes mellitus74474.014.1014.1014.10	Mesenteric	704	37 (5.3)	13 (8.5)	5 (3.9)	3 (2.7)	16 (5.1)			
Right renal70465 (9.2)16 (10.5)12 (9.2)13 (11.8)24 (7.7)Left lower limb70443 (6.1)8 (5.2)8 (6.2)6 (5.5)21 (6.8)Right lower limb70447 (6.7)9 (5.9)7 (5.4)5 (4.6)3 (6.8.4)Any of above704250 (35.5)59 (8.6)43 (3.1)88 (34.6)110 (5.4)Severiy70250.10120 (1.7)20 (1.5.4)32 (3.0.9)64 (7.7)IMH655 (8.01)127 (8.0.0)109 (8.9.9)86 (7.8.2)24 (7.7)deBakey I655 (8.0.1)127 (8.9.0)10 (9.0.1)11 (0.0.1)31 (10.9)Artic valve involvement (actit valve replacement)70458 (8.2)6(3.9)10 (7.7)11 (10.0)31 (10.9)Comorriy Hart disease704495 (7.3)12 (7.2)92 (7.0.8)74 (7.3)12 (9.8)Coronary heart disease704495 (7.3)18 (11.8)10 (9.1)19 (1.9)Marfan syndrome704495 (7.3)18 (11.8)11 (8.5)10 (9.1)19 (1.9)Coronary heart disease70417 (2.4)2 (1.3)5 (3.9)3 (2.7)7 (2.3)Previous cardiac surgery70414 (1.4)0 (0.0)2 (1.5)10 (1.6)3 (1.6)Diabetes mellitus70415 (1.6)16 (1.5)10 (1.6)3 (1.6)3 (1.6)Coronary heart disease7047 (2.4)13 (1.6)15 (1.5)3 (1.6)3 (1.6)Diabetes mellitus70416 (1.	Left renal	704	80 (11.4)	24 (15.7)	10 (7.7)	15 (13.6)	31 (10.0)			
Left lower limb70443 (6.1)8 (5.2)8 (6.2)6 (5.5)21 (6.8)Right lower limb70447 (6.7)9 (5.9)7 (5.4)5 (4.6)26 (8.4)Any of above704250 (3.5)59 (38.6)43 (3.1)38 (34.6)110 (35.4)Severity702 </td <td>Right renal</td> <td>704</td> <td>65 (9.2)</td> <td>16 (10.5)</td> <td>12 (9.2)</td> <td>13 (11.8)</td> <td>24 (7.7)</td>	Right renal	704	65 (9.2)	16 (10.5)	12 (9.2)	13 (11.8)	24 (7.7)			
Right lower limb7047047057054504650465046Any of above704250 (35.5)59 (38.6)43 (33.1)38 (34.6)110 (35.4)Severity702706 (17.0)2 (15.4)2 (20.9)64 (20.7)deBakey I133 (38)26 (7.0)10 (98.3)86 (78.2)240 (77.7)deBakey II7070.0)0 (0.0)1 (0.8)10 (0.9)5 (1.6)Aortic valve involvement (aotric valve replacement or benall root surgery)70458 (8.2)6 (3.9)10 (7.7)11 (10.0)31 (10.9)Comonty Heart disease70495 (70.3)11 (27.3)9 (70.8)7 (467.3)217 (69.8)Coronary heart disease70495 (73.0)11 (16.9)9 (70.8)3 (2.7)7 (2.3)Diabetes mellitus70413 (1.6)0 (0.0)2 (1.5)1 (10.9)8 (2.6)Diabetes mellitus70413 (1.6)0 (0.0)2 (1.5)1 (3.6)5 (1.6)Diabetes mellitus70413 (1.6)10 (1.7)4 (3.6)3 (0.97)Diabetes mellitus70412 (1.7)2 (1.3)2 (1.5)1 (3.6)5 (1.6)Diabetes mellitus70412 (1.7)2 (1.3)1 (1.6)3 (0.7)1 (3.6)3 (0.97)Diabetes mellitus70412 (1.7)2 (1.3)1 (1.6)3 (0.7)1 (3.6)3 (0.97)Diabetes mellitus70412 (1.7)2 (1.3)1 (1.6)3 (0.6)3 (0.6)3 (0.7)Diabetes mellitus	Left lower limb	704	43 (6.1)	8 (5.2)	8 (6.2)	6 (5.5)	21 (6.8)			
Any of above         Total         250 (35.5)         59 (38.6)         43 (33.1)         8 (34.6)         110 (35.4)           Severity         702         Image of the second of the secon	Right lower limb	704	47 (6.7)	9 (5.9)	7 (5.4)	5 (4.6)	26 (8.4)			
Severity         Total         Total         Total         Total         Total         Total           IMH         i         133 (18.9)         26 (17.0)         20 (15.4)         23 (20.9)         64 (20.7)           deBakey I         i         56 (20.1)         127 (83.0)         109 (83.9)         86 (78.2)         240 (77.7)           deBakey II         i         71.0)         0 (0.0)         1 (0.8)         1 (0.9)         5 (1.6)           Acriis valve involvement (aortic valve replacementor Bentall root surgery)         704         88 (82.0)         63.9)         10 (7.7)         11 (10.0)         31 (10.0)           Comorbidities         704         95 (70.3)         112 (73.2)         92 (70.8)         74 (67.3)         217 (69.8)           Coronary heart disease         704         95 (70.3)         112 (73.2)         92 (70.8)         74 (67.3)         217 (69.8)           Coronary heart disease         704         17 (2.4)         2 (1.3)         5 (3.9)         3 (2.7)         7 (2.3)           Previous cardias surgery         704         17 (2.4)         2 (1.3)         5 (3.9)         3 (2.7)         3 (10.0)           Diabetes mellitus         704         13 (1.6)         16 (5.2)         1 (1.6)         0 (0.0)	Any of above	704	250 (35.5)	59 (38.6)	43 (33.1)	38 (34.6)	110 (35.4)			
IMI33 (18.9)26 (17.0)20 (15.4)23 (20.9)64 (20.7)deBakey II562 (80.1)127 (83.0)109 (83.9)86 (78.2)240 (77.7)deBakey III7 (1.0)0 (0.0)1 (0.8)1 (0.9)5 (1.6)Aortic valve involvement (acritic valve replacement or Bentall root surgery)704\$8 (8.2)6 (3.9)10 (7.7)11 (10.0)31 (10.0)ComordiditiesCoronary heart disease704495 (70.3)112 (73.2)92 (70.8)74 (67.3)217 (69.8)Coronary heart disease704495 (70.3)112 (73.2)5 (3.9)3 (2.7)7 (2.3)Previous cardiac surgery70417 (2.4)2 (1.3)5 (3.9)3 (2.7)7 (2.3)Diabetes mellitus70417 (2.4)2 (1.3)5 (3.9)3 (2.7)3 (10.0)Chronic kidney disease70410 (1.4)0 (0.0)2 (1.5)1 (0.9)8 (2.6)Diabetes mellitus7045 (7.5)8 (5.2)10 (7.7)4 (3.6)3 (10.0)Chronic kidney disease704104 (1.48)2 (1.5)1 (1.6)0 (0.7)2 (1.8)3 (1.0)Liver disease7047 (7.0)19 (12.4)13 (1.0,0)15 (1.3)3 (1.0)1 (1.6)Diabytis7042 (1.8)2 (1.8)2 (1.8)3 (1.0)3 (1.0)1 (1.6)Coronary heart disease70410 (1.8)2 (1.5)1 (1.6)3 (0.7)3 (1.0)Liver disease70412 (1.4)13 (1.2)1 (	Severity	702	. ,				. ,			
deBakey I         Image: Constraint of the section of the sectio	IMH		133 (18.9)	26 (17.0)	20 (15.4)	23 (20.9)	64 (20.7)			
Construction         Construction         Construction         Construction         Construction           deBakey II         Construction         Colo         6(0.0)         1(0.8)         1(0.0)         5(1.6)           Acritic valve involvement (aortic valve replacement or Bental root surgery)         704         58 (8.2)         6(3.9)         10 (7.7)         11 (10.0)         217 (69.8)           Comorbidities          704         58 (8.2)         18 (11.8)         11 (8.5)         10 (9.1)         19 (6.1)           Coronary heart disease         704         58 (8.2)         18 (11.8)         11 (8.5)         10 (9.1)         19 (6.1)           Marfan syndrome         704         17 (2.4)         2 (1.3)         5 (3.9)         3 (2.7)         7 (2.3)           Previous cardiac surgery         704         11 (1.6)         0 (0.0)         2 (1.5)         15 (1.6)         50 (16.1)           Diabetes mellitus         704         13 (1.4)         6 (1.5)         15 (1.6)         50 (16.1)           Dialysis         704         14 (1.7)         14 (1.0)         15 (1.5)         51 (3.6)         50 (16.1)           Dialysis         704         12 (1.7)         2 (1.3)         2 (1.8)         15 (1.6)         21 (8.0)         7 (	deBakey I		562 (80.1)	127 (83.0)	109 (83.9)	86 (78.2)	240 (77.7)			
Construction         Construction         Construction         Construction         Construction         Construction           Comorbidities         58 (8.2)         6 (3.9)         10 (0.7)         11 (10.0)         31 (10.0)           Comorbidities         58 (8.2)         6 (3.9)         12 (7.3)         24 (67.3)         217 (69.8)           Coronary heart disease         704         495 (70.3)         112 (73.2)         92 (70.8)         3 (2.7)         7 (2.3)           Marfan syndrome         704         17 (2.4)         2 (1.3)         5 (3.9)         3 (2.7)         7 (2.3)           Previous cardiac surgery         704         11 (1.6)         0 (0.0)         2 (1.5)         1 (0.9)         8 (2.6)           Diabets mellitus         704         53 (7.5)         8 (5.2)         10 (7.7)         4 (3.6)         3 (10.0)           Chronic kidney disease         704         14 (1.4)         2 (1.5)         1 (3.6)         5 (6.1)           Diabysis         704         12 (1.7)         2 (1.3)         1 (1.6)         3 (0.0)         1 (3.6)         3 (0.7)           Liver disease         704         12 (1.7)         2 (1.3)         6 (4.5)         3 (4.9)         1 (4.9)           COPD         704         3	deBakey II		7 (1.0)	0 (0.0)	1 (0.8)	1 (0.9)	5 (1.6)			
Bentall root surgery)         Note of the origination of the originatis originatis and the originatis origination of the origination	Aortic valve involvement (aortic valve replacement or			- ()						
Comorbidities           Hypertension         704         495 (70.3)         12 (73.2)         9 2 (70.8)         7 (46.7.3)         12 (76.9.8)           Coronary heart disease         704         58 (8.2)         18 (18.0)         11 (8.5)         10 (9.1)         19 (6.1)           Marfan syndrome         704         17 (2.4)         2 (1.3)         5 (3.9)         3 (2.7)         7 (2.3)           Previous cardia surgery         704         11 (1.6)         0 (0.0)         2 (1.5)         1 (0.9)         8 (2.6)           Diabetes mellitus         704         53 (7.5)         8 (5.2)         10 (7.7)         4 (3.6)         31 (1.0.0)           Chronic kidney disease         704         10 (1.8)         24 (15.7)         15 (11.5)         15 (13.6)         30 (0.7)           Liver disease         704         12 (1.7)         2 (1.3)         2 (1.8)         2 (1.8)         30 (9.7)           Atrial fibrillation         704         12 (1.7)         2 (1.3)         8 (6.2)         6 (5.5)         2 (1.6.8)           OPD         704         12 (1.7)         14 (9.2)         8 (6.2)         6 (5.5)         13 (4.2)           Dialysis         704         12 (1.7)         12 (0.9)         2 (1.8)         12 (1.8) <td>Bentall root surgery)</td> <td>704</td> <td>58 (8.2)</td> <td>6 (3.9)</td> <td>10 (7.7)</td> <td>11 (10.0)</td> <td>31 (10.0)</td>	Bentall root surgery)	704	58 (8.2)	6 (3.9)	10 (7.7)	11 (10.0)	31 (10.0)			
Hypertension         704         495 (70.3)         112 (73.2)         92 (70.8)         74 (67.3)         217 (69.8)           Coroary heart disease         704         58 (8.2)         18 (1.8)         11 (8.5)         10 (9.1)         19 (6.1)           Marfan syndrome         704         17 (2.4)         2 (1.3)         5 (3.9)         3 (2.7)         7 (2.3)           Previous cardia surgery         704         11 (1.6)         0 (0.0)         2 (1.5)         1 (0.9)         8 (2.6)           Diabetes mellitus         704         53 (7.5)         8 (5.2)         10 (7.7)         4 (3.6)         3 (10.0)           Chronic kidney disease         704         104 (14.8)         24 (15.7)         15 (1.5)         15 (1.3.6)         5 (1.6)           Diabets mellitus         704         104 (14.8)         24 (15.7)         13 (10.0)         15 (1.3.6)         3 (0.7)           Liver disease         704         104 (1.8)         24 (1.5.7)         13 (10.0)         15 (1.3.6)         3 (0.7)           Atrial fibrillation         704         70.90         19 (12.4)         13 (10.0)         15 (1.3.6)         13 (4.2)           Old stroke         704         10.40         0.3.9         6 (4.5.1)         10.6.9         13 (2.9)	Comorbidities	1	ſ	1	r	1	r			
Coronary heart disease         704         \$8 (8.2)         18 (11.8)         11 (8.5)         10 (9.1)         19 (6.1)           Marfan syndrome         704         17 (2.4)         2 (1.3)         5 (3.9)         3 (2.7)         7 (2.3)           Previous cardiac surgery         704         11 (1.6)         0 (0.0)         2 (1.5)         1 (0.9)         8 (2.6)           Diabets mellitus         704         37 (5.7)         8 (5.2)         10 (7.7)         4 (3.6)         3 (1.0.0)           Chronic kidney disease         704         104 (1.8)         2 (1.5)         15 (1.3.6)         5 (1.6.1)           Dialysis         704         12 (1.7)         2 (1.3)         2 (1.5)         2 (1.8)         3 (0.6.1)           Liver disease         704         7 (10.9)         19 (12.4)         13 (10.0)         15 (1.6.3)         3 (0.7)           COPD         704         47 (1.9)         14 (2.9.2)         8 (6.2)         6 (5.5)         13 (4.2)           Old stroke         704         13 (4.4)         6 (3.9)         6 (4.6)         6 (5.9)         13 (4.2)           Previous cardiac surgery         704         16 (1.6)         2 (1.6)         2 (1.8)         2 (1.6)           Previous cardia surgery         704 <td>Hypertension</td> <td>704</td> <td>495 (70.3)</td> <td>112 (73.2)</td> <td>92 (70.8)</td> <td>74 (67.3)</td> <td>217 (69.8)</td>	Hypertension	704	495 (70.3)	112 (73.2)	92 (70.8)	74 (67.3)	217 (69.8)			
Marfan syndrome         704         7(2.4)         2(1.3)         5(3.9)         3(2.7)         7(2.3)           Previous cardiac surgery         704         11(1.6)         0(0.0)         2(1.5)         1(0.9)         8(2.6)           Diabets mellitus         704         53(7.5)         8(5.2)         10(7.7)         4(3.6)         31(10.0)           Chronic kidney disease         704         12(1.7)         2(1.3)         15(1.5)         15(13.6)         50(16.1)           Dialysis         704         12(1.7)         2(1.3)         2(1.5)         2(1.8)         6(1.9)           Liver disease         704         70(10.9)         19(12.4)         13(10.0)         15(13.6)         30(9.7)           Atrial fibrillation         704         97(10.9)         19(12.4)         6(6.2)         6(5.5)         13(4.2)           ODP         704         14(4.9)         6(3.9)         6(4.6)         6(5.5)         13(4.2)           Old stroke         704         11(1.6)         0(0.0)         2(1.5)         10.9)         8(2.6)           Previous cardiac surgery         704         11(1.6)         0(0.0)         2(1.5)         10.9)         8(2.6)           Preoperatide surgery         704         10	Coronary heart disease	704	58 (8.2)	18 (11.8)	11 (8.5)	10 (9.1)	19 (6.1)			
Previous cardiac surgery         704         11 (1.6)         0 (0.0)         2 (1.5)         1 (0.9)         8 (2.6)           Diabetes mellitus         704         53 (7.5)         8 (5.2)         10 (7.7)         4 (3.6)         31 (10.0)           Chronic kidney disease         704         104 (14.8)         24 (15.7)         15 (11.5)         15 (13.6)         50 (16.1)           Dialysis         704         12 (1.7)         2 (1.3)         2 (1.5)         2 (1.8)         6 (9.9)           Liver disease         704         12 (1.7)         19 (12.4)         13 (10.0)         15 (13.6)         30 (9.7)           Atrial fibrillation         704         97 (10.9)         19 (12.4)         13 (10.0)         15 (13.6)         30 (9.7)           OLDys         704         97 (10.9)         14 (9.2)         8 (6.2)         6 (5.5)         16 (8.9)           COPD         704         31 (4.9)         6 (3.9)         6 (4.6)         6 (5.5)         13 (4.2)           Old stroke         704         12 (1.6)         7 (4.0)         7 (4.9)         14 (9.7)         12 (9.7)           Previous cardia surgery         704         12 (1.6)         0 (0.0)         2 (1.5)         10 (9.1)         12 (9.7)           Pr	Marfan syndrome	704	17 (2.4)	2 (1.3)	5 (3.9)	3 (2.7)	7 (2.3)			
Diabetes mellitus70453 (7.5)8 (5.2)10 (7.7)4 (3.6)31 (1.0)Chronic kidney disease704104 (14.8)24 (15.7)15 (11.5)15 (13.6)50 (16.1)Dialysis70412 (1.7)2 (1.3)2 (1.5)2 (1.8)6 (1.9)Liver disease70477 (10.9)19 (12.4)13 (10.0)15 (13.6)30 (9.7)Atrial fibrillation70497 (10.9)14 (9.2)8 (6.2)6 (5.5)21 (6.8)COPD70431 (4.4)6 (3.9)6 (4.6)6 (5.5)13 (4.2)Old stroke7047047 (4.6)7 (5.4)2 (1.8)12 (3.9)Previous cardia surgery70411 (1.6)0.002 (1.5)10.9)8 (2.6)Pre-op conditions704106 (15.1)2 (16.3)2 (18.1)12 (3.9)12 (3.9)Pre-operative lab data70410.6 (15.1)2 (16.3)2 (18.1)12 (1.6)5 (16.7)Pre-operative lab data61.11.5 ± 1.71.3 ± 0.91.4 ± 0.91.5 ± 1.61.5 ± 1.6Well child c	Previous cardiac surgery	704	11 (1.6)	0 (0.0)	2 (1.5)	1 (0.9)	8 (2.6)			
Chronic kidney disease         704         104 (14.8)         24 (15.7)         15 (11.5)         15 (13.6)         50 (16.1)           Dialysis         704         12 (1.7)         2 (1.3)         2 (1.5)         2 (1.8)         6 (1.9)           Liver disease         704         77 (10.9)         19 (12.4)         13 (10.0)         15 (13.6)         30 (9.7)           Atrial fibrillation         704         49 (7.0)         14 (9.2)         8 (6.2)         6 (5.5)         21 (6.8)           COPD         704         31 (4.4)         6 (3.9)         6 (4.6)         6 (5.5)         13 (4.2)           Old stroke         704         14 (1.6)         0 (0.0)         2 (1.8)         12 (3.9)           Previous cardiac surgery         704         11 (1.6)         0 (0.0)         2 (1.5)         1 (0.9)         8 (2.6)           Pre-op conditions         704         106 (15.1)         2 (16.3)         2 (418.5)         5 (4.6)         5 (16.7)           Pre-op conditions         704         106 (15.1)         2 (16.3)         2 (418.5)         5 (4.6)         5 (16.7)           Pre-op conditions         704         106 (15.1)         2 (16.3)         14 (18.9)         1.4 (19.9)         1.5 (1.6)           Mcreative lad	Diabetes mellitus	704	53 (7.5)	8 (5.2)	10 (7.7)	4 (3.6)	31 (10.0)			
Dialysis         704         12 (1.7)         2 (1.3)         2 (1.5)         2 (1.8)         6 (1.9)           Liver disease         704         77 (10.9)         19 (12.4)         13 (10.0)         15 (13.6)         30 (9.7)           Atrial fibrillation         704         49 (7.0)         14 (9.2)         8 (6.2)         6 (5.5)         21 (6.8)           COPD         704         31 (4.4)         6 (3.9)         6 (4.6)         6 (5.5)         13 (4.2)           Old stroke         704         28 (4.0)         7 (4.6)         7 (5.4)         2 (1.8)         12 (3.9)           Previous cardiac surgery         704         11 (1.6)         0 (0.0)         2 (1.5)         1 (0.9)         8 (2.6)           Pre-op conditions         704         106 (15.1)         2 (16.3)         2 4 (18.5)         5 (4.6)         5 2 (16.7)           Preoperative lad dat         704         106 (15.1)         2 5 (16.3)         2 4 (18.5)         5 (4.6)         5 2 (16.7)           WBC, 10 <sup>3</sup> /uL         681         1.4±1.4         1.5±1.7         1.3±0.9         1.4±0.9         1.5±1.6           WBC, 10 <sup>3</sup> /uL         699         13.1±4.8         12.8±4.3         13.1±4.6         12.5±1.5         13.4±5.2           Platele	Chronic kidney disease	704	104 (14.8)	24 (15.7)	15 (11.5)	15 (13.6)	50 (16.1)			
Liver disease70477 (10.9)19 (12.4)13 (10.0)15 (13.6)30 (9.7)Atrial fibrillation70449 (7.0)14 (9.2)8 (6.2)6 (5.5)21 (6.8)COPD70431 (4.4)6 (3.9)6 (4.6)6 (5.5)13 (4.2)Old stroke70428 (4.0)7 (4.6)7 (5.4)2 (1.8)8 (2.6)Previous cardia surgery70410 (1.6)0 (0.0)2 (1.5)10.9)8 (2.6)Pre-op conditions704106 (15.1)25 (16.3)24 (18.5)5 (4.6)5 2 (16.7)Preoperative lab data704106 (15.1)25 (16.3)24 (18.5)5 (4.6)5 2 (16.7)Creatinine, mg/dL6811.4 ± 1.41.5 ± 1.71.3 ± 0.91.4 ± 0.91.5 ± 1.6WBC, 10 <sup>3</sup> /uL69913.1 ± 4.812.8 ± 4.313.1 ± 4.61.5 ± 1.5 ± 1.51.3 ± 0.91.4 ± 0.91.3 ± 2.5 ± 1.5Platelet, 1000/uL6991.7 ± 6.65.5176.7 ± 6.817.6 ± 5.5 ± 1.5	Dialysis	704	12 (1.7)	2 (1.3)	2 (1.5)	2 (1.8)	6 (1.9)			
Atrial fibrillation70449(7.0)14(9.2)8(6.2)6(5.5)21(6.8)COPD70431(4.4)6(3.9)6(4.6)6(5.5)13(4.2)Old stroke70428(4.0)7(4.6)7(5.4)2(1.8)12(3.9)Previous cardiac surgery70411(1.6)0(0.0)2(1.5)10.9)8(2.6)Pre-op conditions54(8.5)5(4.6)5(4.6)5(1.6)5(1.6)Preoperative lab data704106 (15.1)25 (16.3)24 (18.5)5(4.6)5(1.6)Preoperative lab data6811.4±1.41.5±1.71.3±0.91.4±0.91.5±1.6WBC, 10 <sup>3</sup> /uL69913.1±4.81.2±4.31.1±4.61.5±4.51.3±5.21.3±5.21.3±5.1.91.3±5.2Platelet, 1000/uL6991.3±2.11.3±2.01.3±5.21.3±1.91.3±2.11.3±2.11.3±2.11.3±1.91.3±2.1BUN, mg/dL6991.7±1.62.1±1.01.9±1.11.9±1.11.9±1.11.9±1.2	Liver disease	704	77 (10.9)	19 (12.4)	13 (10.0)	15 (13.6)	30 (9.7)			
COPD         704         31 (4.4)         6 (3.9)         6 (4.6)         6 (5.5)         13 (4.2)           Old stroke         704         28 (4.0)         7 (4.6)         7 (5.4)         2 (1.8)         12 (3.9)           Previous cardiac surgery         704         11 (1.6)         0 (0.0)         2 (1.5)         1 (0.9)         8 (2.6)           Pre-op conditions         704         106 (15.1)         25 (16.3)         24 (18.5)         5 (4.6)         5 (16.7)           Preoperative lab data         704         106 (15.1)         25 (16.3)         24 (18.5)         5 (4.6)         5 (16.7)           Preoperative lab data         704         106 (15.1)         25 (16.3)         24 (18.5)         5 (4.6)         5 (16.7)           WBC, 10 <sup>3</sup> /uL         681         1.4 ± 1.4         1.5 ± 1.7         1.3 ± 0.9         1.4 ± 0.9         1.5 ± 1.6           WBC, 10 <sup>3</sup> /uL         699         13.1 ± 4.8         1.2 ± 4.3         13.1 ± 4.6         12.5 ± 4.5         13.4 ± 5.2           Platelet, 1000/uL         699         13.4 ± 2.1         13.5 ± 2.0         13.5 ± 1.9         13.2 ± 2.1           BUN, mg/dL         699         19.7 ± 11.6         12.2 ± 1.20         19.7 ± 1.4         19.5 ± 11.1         19.1 ± 1.2 <td>Atrial fibrillation</td> <td>704</td> <td>49 (7.0)</td> <td>14 (9.2)</td> <td>8 (6.2)</td> <td>6 (5.5)</td> <td>21 (6.8)</td>	Atrial fibrillation	704	49 (7.0)	14 (9.2)	8 (6.2)	6 (5.5)	21 (6.8)			
Old stroke         704         28 (4.0)         7 (4.6)         7 (5.4)         2 (1.8)         12 (3.9)           Previous cardiac surgery         704         11 (1.6)         0 (0.0)         2 (1.5)         1 (0.9)         8 (2.6)           Pre-op conditions         704         106 (15.1)         25 (16.3)         24 (18.5)         5 (4.6)         5 (16.7)           Preoperative lab data         704         106 (15.1)         25 (16.3)         24 (18.5)         5 (4.6)         5 (16.7)           Preoperative lab data         704         106 (15.1)         25 (16.3)         1.4 ± 0.9         1.5 ± 1.6           WBC, 10 <sup>3</sup> /uL         681         1.4 ± 1.4         1.5 ± 1.7         1.3 ± 0.9         1.4 ± 0.9         1.5 ± 1.6           WBC, 10 <sup>3</sup> /uL         699         13.1 ± 4.8         1.2 ± 4.3         13.1 ± 4.6         12.5 ± 4.5         13.4 ± 5.2           Platelet, 1000/uL         699         13.4 ± 2.1         13.5 ± 2.0         13.5 ± 1.9         13.2 ± 2.1           Hemoglobin, g/dL         699         19.7 ± 11.6         21.2 ± 12.0         19.7 ± 10.4         19.5 ± 11.1         19.1 ± 12.2           Continued         499         19.7 ± 11.6         21.2 ± 12.0         19.7 ± 10.4         19.5 ± 11.1         19.1 ± 12.2	COPD	704	31 (4.4)	6 (3.9)	6 (4.6)	6 (5.5)	13 (4.2)			
Previous cardiac surgery         704         11 (1.6)         0 (0.0)         2 (1.5)         1 (0.9)         8 (2.6)           Pre-op conditions         Tamponade/Shock         704         106 (15.1)         25 (16.3)         24 (18.5)         5 (4.6)         52 (16.7)           Preoperative lab data         Creatinine, mg/dL         681         1.4 ± 1.4         1.5 ± 1.7         1.3 ± 0.9         1.4 ± 0.9         1.5 ± 1.6           WBC, 10 <sup>3</sup> /uL         699         13.1 ± 4.8         12.8 ± 4.3         13.1 ± 4.6         12.5 ± 4.5         13.4 ± 5.2           Platelet, 1000/uL         699         179.6 ± 66.5         176.7 ± 64.8         173.6 ± 55.2         181.0 ± 60.3         183.1 ± 73.5           Hemoglobin, g/dL         699         13.4 ± 2.1         13.5 ± 2.0         13.5 ± 1.9         13.2 ± 2.1           BUN, mg/dL         499         19.7 ± 11.6         21.2 ± 12.0         19.7 ± 10.4         19.5 ± 11.1         19.1 ± 12.2	Old stroke	704	28 (4.0)	7 (4.6)	7 (5.4)	2 (1.8)	12 (3.9)			
Pre-op conditions         Tamponade/Shock         704         106 (15.1)         25 (16.3)         24 (18.5)         5 (4.6)         52 (16.7)           Preoperative lab data         5         13         5         13	Previous cardiac surgery	704	11 (1.6)	0 (0.0)	2 (1.5)	1 (0.9)	8 (2.6)			
Tamponade/Shock         704         106 (15.1)         25 (16.3)         24 (18.5)         5 (4.6)         52 (16.7)           Preoperative lab data               5 (16.7)         5 (16.7)           Creatinine, mg/dL         681         1.4 ± 1.4         1.5 ± 1.7         1.3 ± 0.9         1.4 ± 0.9         1.5 ± 1.6           WBC, 10 <sup>3</sup> /uL         699         13.1 ± 4.8         12.8 ± 4.3         13.1 ± 4.6         12.5 ± 4.5         13.4 ± 5.2           Platelet, 1000/uL         699         179.6 ± 66.5         176.7 ± 64.8         173.6 ± 55.2         181.0 ± 60.3         183.1 ± 73.5           Hemoglobin, g/dL         699         13.4 ± 2.1         13.5 ± 2.0         13.5 ± 2.1         13.5 ± 1.9         13.2 ± 2.1           BUN, mg/dL         499         19.7 ± 11.6         21.2 ± 12.0         19.7 ± 10.4         19.5 ± 11.1         19.1 ± 12.2	Pre-op conditions						·			
Preoperative lab data         Image: Creatinine, mg/dL         681         1.4±1.4         1.5±1.7         1.3±0.9         1.4±0.9         1.5±1.6           WBC, 10 <sup>3</sup> /uL         699         13.1±4.8         12.8±4.3         13.1±4.6         12.5±4.5         13.4±5.2           Platelet, 1000/uL         699         179.6±66.5         176.7±64.8         173.6±55.2         181.0±60.3         183.1±73.5           Hemoglobin, g/dL         699         13.4±2.1         13.5±2.0         13.5±2.1         13.5±1.9         13.2±2.1           BUN, mg/dL         499         19.7±11.6         21.2±12.0         19.7±10.4         19.5±11.1         19.1±12.2	Tamponade/Shock	704	106 (15.1)	25 (16.3)	24 (18.5)	5 (4.6)	52 (16.7)			
Greatine, mg/dL         681         1.4±1.4         1.5±1.7         1.3±0.9         1.4±0.9         1.5±1.6           WBC, 10 <sup>3</sup> /uL         699         13.1±4.8         12.8±4.3         13.1±4.6         12.5±4.5         13.4±5.2           Platelet, 1000/uL         699         179.6±66.5         176.7±64.8         173.6±55.2         181.0±60.3         183.1±73.5           Hemoglobin, g/dL         699         13.4±2.1         13.5±2.0         13.5±2.1         13.5±1.9         13.2±2.1           BUN, mg/dL         499         19.7±11.6         21.2±12.0         19.7±10.4         19.5±11.1         19.1±12.2	Preoperative lab data	1	1	1	1	1	<u> </u>			
WBC, 10 <sup>3</sup> /uL         699         13.1 ± 4.8         12.8 ± 4.3         13.1 ± 4.6         12.5 ± 4.5         13.4 ± 5.2           Platelet, 1000/uL         699         179.6 ± 66.5         176.7 ± 64.8         173.6 ± 55.2         181.0 ± 60.3         183.1 ± 73.5           Hemoglobin, g/dL         699         13.4 ± 2.1         13.5 ± 2.0         13.5 ± 2.1         13.5 ± 1.9         13.2 ± 2.1           BUN, mg/dL         499         19.7 ± 11.6         21.2 ± 12.0         19.7 ± 10.4         19.5 ± 11.1         19.1 ± 12.2	Creatinine, mg/dL	681	$1.4 \pm 1.4$	1.5±1.7	$1.3 \pm 0.9$	1.4±0.9	1.5±1.6			
Platelet, 1000/uL         699         179.6±66.5         176.7±64.8         173.6±55.2         181.0±60.3         183.1±73.5           Hemoglobin, g/dL         699         13.4±2.1         13.5±2.0         13.5±2.1         13.5±1.9         13.2±2.1           BUN, mg/dL         499         19.7±11.6         21.2±12.0         19.7±10.4         19.5±11.1         19.1±12.2	WBC, 10 <sup>3</sup> /uL	699	13.1±4.8	12.8±4.3	13.1±4.6	12.5±4.5	13.4±5.2			
Hemoglobin, g/dL         699         13.4 ± 2.1         13.5 ± 2.0         13.5 ± 2.1         13.5 ± 1.9         13.2 ± 2.1           BUN, mg/dL         499         19.7 ± 11.6         21.2 ± 12.0         19.7 ± 10.4         19.5 ± 11.1         19.1 ± 12.2	Platelet, 1000/uL	699	179.6+66.5	176.7 + 64.8	173.6±55.2	181.0±60.3	183.1 + 73.5			
BUN, mg/dL         499         19.7 ± 11.6         21.2 ± 12.0         19.7 ± 10.4         19.5 ± 11.1         19.1 ± 12.2           Continued	Hemoglobin, g/dL	699	13.4±2.1	$13.5 \pm 2.0$	13.5±2.1	13.5±1.9	13.2±2.1			
Continued	BUN. mg/dL	499	197+116	21 2 + 12 0	197+104	195+111	191+122			
	Continued									

			Number of ATAAD surgery of the surgeon					
Variable	Valid N	Total (N=704)	$\leq$ 10th (n = 153)	11th to 20th (n=130)	21th to 30th (n=110)	> 30th (n = 311)		
Sodium, mg/dL	691	138.9±3.4	139.0±3.8	139.3±3.8	139.2±2.8	138.6±3.3		
Potassium, mg/dL	692	$3.8 \pm 0.6$	$3.7\pm0.5$	$3.8 \pm 0.5$	3.8±0.6	$3.8 \pm 0.6$		
Albumin, mg/dL	171	$3.2 \pm 0.6$	$3.3\pm0.5$	$3.4 \pm 0.5$	3.2±0.6	$3.2 \pm 0.6$		
HbA1c, %	181	$6.0 \pm 0.7$	$6.0\pm0.7$	$6.0 \pm 0.6$	$5.9 \pm 0.4$	$6.1\pm0.8$		
AST, U/L	413	38 [26, 64]	38 [26, 63]	42 [30, 72]	37 [25, 67]	37 [26, 65]		
ALT, U/L	493	26 [19, 43]	24 [19, 38]	29 [19, 53]	23 [17, 44]	26 [19, 43]		
INR	677	$1.15 \pm 0.25$	$1.16 \pm 0.37$	$1.14 \pm 0.16$	1.12±0.13	$1.15 \pm 0.24$		
Post-operative lab data								
Platelet, 1000/uL	672	$136.4 \pm 45.0$	$131.5\pm42.8$	$137.2 \pm 44.2$	147.8±52.0	$134.5 \pm 43.2$		
Hemoglobin, g/dL	672	$10.7 \pm 1.7$	$10.9 \pm 1.6$	$10.9 \pm 1.7$	$10.8 \pm 1.7$	$10.6 \pm 1.6$		
AST, U/L	469	85 [54, 174]	91 [58, 177]	102 [57, 187]	76 [57, 141]	81 [53, 189]		
ALT, U/L	458	45 [25, 101]	43 [23, 103]	55 [27, 111]	46 [27, 93]	44 [25, 105]		
Lactic acid	253	$62.9 \pm 47.9$	$71.3\pm40.2$	81.0±76.8	53.4±32.2	$59.7 \pm 43.4$		
Proteinuria	183	30 [15, 100]	30 [15, 100]	30 [15, 100]	30 [0, 100]	30 [15, 100]		
SOFA score	276	$10.7 \pm 2.2$	$11.1 \pm 1.9$	$10.4 \pm 1.9$	$10.7 \pm 2.4$	$10.7 \pm 2.3$		
Surgical data								
Brain protection	704							
Antegrade		368 (52.3)	62 (40.5)	65 (50.0)	59 (53.6)	182 (58.5)		
Retrograde		336 (47.7)	91 (59.5)	65 (50.0)	51 (46.4)	129 (41.5)		
HTK, cc	303	$2196\pm573$	$2003\pm553$	$2225\pm561$	$2134 \pm 530$	$2250\pm588$		
Cerebral perfusion, min	298	$49.0\pm22.0$	$44.7 \pm 17.9$	50.0±23.0	$44.5 \pm 14.5$	51.6±23.9		
Surgical extension								
Partial or total aortic arch replacement	704	224 (31.8)	56 (36.6)	43 (33.1)	41 (37.3)	84 (27.0)		
Aortic root replacement	704	47 (6.7)	4 (2.6)	6 (4.6)	10 (9.1)	27 (8.7)		
Elephant trunk	704	23 (3.3)	1 (0.7)	5 (3.9)	1 (0.9)	16 (5.1)		
Ascending aorta replacement only	704	417 (59.2)	93 (60.8)	77 (59.2)	58 (52.7)	189 (60.8)		

**Table 1.** Baseline characteristics of the patients according to the cumulative operation volume of the surgeon. *ATAAD* acute type A aortic dissection, *BMI* body mass index, *IMH* intramural hematoma, *COPD* chronic obstructive pulmonary disease, *WBC* whole blood cell, *BNP* B-type natriuretic peptide, *BUN* blood urea nitrogen, *HCO*<sub>3</sub> bicarbonate, *HbA1c* glycated hemoglobin, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *INR* international normalized ratio. Data were presented as frequency (percentage) or mean ± standard deviation or median [Quartile 1, Quartile 3].

considerably requires sustained attention, this thus renders such surgery a challenging task for aging surgeons. Accordingly, before surgeons are allowed to independently perform surgery for ATAAD, they must be provided with the relevant training that can enable them to achieve ideal perioperative outcomes.

Regarding surgery for ATAAD, studies have explored the relationship between either surgeon cumulative operative volume or hospital volume and patient outcomes and have reported nearly identical results<sup>11,14-16</sup>. A larger operative volume is associated with more favorable patient outcomes. This finding is consistent with that of our analysis of cumulative operative volume per surgeon (Fig. 1B). However, current evidence cannot explicitly identify the learning curve of a junior surgeon because related studies are limited to the annual hospital volume, cumulative hospital volume, cumulative surgeon volume, or annual surgeon volume. Due to incapability of defining each surgeon's sequential volume of surgery, outcome analysis results could be obscured by the lack of data regarding the chronological relationship among surgical procedures for each surgeon. A surgeon's initial surgical performance may bias their subsequent surgical performance when conducting outcome analysis. In such situations, the optimal operative volume required for a surgeon to achieve optimal ATAAD treatment outcomes could not be determined. We used data on the sequential operative volume of surgeons, including their every index operations, to analyze the relationship between operative volume and patient outcomes.

We analyzed 704 patients with a first-time diagnosis of ATAAD who received surgery; the results revealed a relatively low mortality rate for these patients (10.8%). This low mortality rate reflects that most patients with ATAAD in the CGRD were operated in the tertiary center. More ATAAD cases would be encountered in such aortic center in certain time period. Additionally, this finding can be attributed to the advanced recognition, increased clinical suspicion, and improved management of ATAAD<sup>21</sup>. Our results also reveal a significant learning curve for surgical repair of ATAAD. The relationship of in-hospital mortality rate, composite event rate, and length of ICU stay with surgeon operative volume exhibited a significant sliding trend. This demonstrates that increased operative volume is associated with improved outcomes and surgery related parameters.

			Number of ATAAD surgery of the surgeon							
Subgroup	No. of patients	Total	≤10th	11th to 20th	21st to 30th	>30th	P trend			
Overall		76 (10.8)	23 (15.0)	17 (13.1)	8 (7.3)	28 (9.0)	0.031			
Surgical extension										
No (ascending only)	417	37 (8.9)	12 (12.9)	7 (9.1)	3 (5.2)	15 (7.9)	0.184			
Yes (any extension)	287	39 (13.6)	11 (18.3)	10 (18.9)	5 (9.6)	13 (10.7)	0.080			
Malperfusion syndrome										
No	454	42 (9.3)	11 (11.7)	13 (14.9)	4 (5.6)	14 (7.0)	0.056			
Yes	250	34 (13.6)	12 (20.3)	4 (9.3)	4 (10.5)	14 (12.7)	0.290			
Tamponade/Shock										
No	598	58 (9.7)	16 (12.5)	12 (11.3)	6 (5.7)	24 (9.3)	0.249			
Yes	106	18 (17.0)	7 (28.0)	5 (20.8)	2 (40.0)	4 (7.7)	0.022			
Duration between the onset (the arrival at the emergent department) and entering the operating room										
<1.8 h	323	37 (11.5)	5 (9.1)	7 (13.2)	5 (10.2)	20 (12.1)	0.691			
≥1.8 h	365	38 (10.4)	18 (18.8)	10 (13.5)	3 (5.6)	7 (5.0)	< 0.001			
Extent of dissection/Severity										
IMH	133	8 (6.0)	2 (7.7)	1 (5.0)	0 (0.0)	5 (7.8)	0.883			
deBakey I	562	68 (12.1)	21 (16.5)	16 (14.7)	8 (9.3)	23 (9.6)	0.032			
deBakey II	7	0 (0.0)	NA	0 (0.0)	0 (0.0)	0 (0.0)	NA			
Aortic valve involvement										
No	646	71 (11.0)	22 (15.0)	17 (14.2)	8 (8.1)	24 (8.6)	0.022			
Yes	58	5 (8.6)	1 (16.7)	0 (0.0)	0 (0.0)	4 (12.9)	0.585			

**Table 2.** In-hospital mortality of the patients according to the cumulative operation volume of the surgeon bydifferent subgroups. ATAAD acute type A aortic dissection, ICU intensive care unit, NA not applicable.

.....

When analyzing the impact of preoperative clinical condition and surgical procedure on in-hospital mortality, we found that the high-volume surgeon group would achieve better outcome in more severe clinical condition, such as pre-operative tamponade or shock, longer duration from onset to operation room, and deBakey I aortic dissection. More complicated surgical procedure, for those with surgeries involving any surgical extension, demonstrated similar relationships.

We defined an ideal mortality rate for surgical repair of ATAAD as an in-hospital patient mortality rate of < 10%. We found that surgeons with a cumulative operative volume of > 25 could achieve this ideal rate, on average. This can thus be set as the target volume for junior surgeons, which can enable them to achieve optimal outcomes and operate independently without a supervisor. However, in addition to operative volume, frequency plays a major role in achieving favorable outcomes. After comparing the training period of junior surgeons achieving 25 operations during the study period, we observed that a long training period can eliminate the positive effect of a large operative volume (Fig. 3). Hence, this finding confirms that fostering high-volume surgeons at high-volume hospitals can achieve the best outcome in terms of in-hospital mortality prevention. This is because high-volume hospitals such as tertiary referral centers encounter frequent ATAAD cases. In addition, high-volume surgeons<sup>22</sup>. Therefore, setting an adequate cooperation policy for junior surgeons is crucial to ensure improved surgical outcomes, as is establishing an aortic center or aortic subspecialty within a hospital to specialize in aortic surgery. This can not only facilitate the rapid accumulation of relevant experiences but also provide a robust backup and supervision system for patient surgery.

**Limitation.** The study has multiple limitations. First, we could not systematically analyze the assistance involved in the operation, because no related detail, such as the experience or the assisting time of each supervisor during the operation. However, the trainees in the Chang Gung Memorial Hospital systems had been limited for research fellows majoring in cardiovascular surgery. We consider the influence of the supervisor would gradually diminish as the operator's volume increased, which would not be the significant cause for the improving outcome related to increased volume demonstrated in the study. Second, although the CGRD is the largest hospital-based database in Taiwan, our result should not be directly generalized to other medical institutions. Considering different hospital scales, the optimal operative volume of 25 suggested in this study might differ for other hospitals. Third, there might be generation effect in surgical outcome due to the evolution in perioperative care and surgical technique of ATAAD in recent years. The junior surgeons trained in recent years might achieve a better outcome in their early career surgeries compared to those trained in older years because standing on the shoulder of the giant. Finally, because of our study's retrospective design, we could infer only associations rather than causation.



**Figure 2.** The relationship between the surgeon experience volume (defined as the number of AAD surgery of the surgeon) and the in-hospital mortality rate (**A**), the proportion of composite event (**B**), clamp time (**C**), and length of ICU stay (**D**). Composite event is anyone of in-hospital mortality, new-onset stroke, new-onset dialysis, respiratory failure, use of extracorporeal membrane oxygenation, and massive blood transfusion (packed red blood cell > 10U). Each point consists of 2 sequential numbers of operation volume among the 1st to 19th operations of the surgeon, 5 sequential numbers of operation volume among the 20th to 39th operations of the surgeon, and 10 sequential numbers of operation volume after the 40th operations of the surgeon, respectively. ICU, intensive care unit.

#### Conclusion

Surgery for ATAAD involves a prominent learning curve in terms of improving clinical outcomes and achieving surgical safety. We observed that surgeons with a cumulative operative volume of > 25 could achieve the goal of an in-hospital patient mortality rate of < 10%; however, a relatively long training period might eliminate the positive effect engendered by a large operative volume. Hence, we suggest that fostering high-volume surgeons at high-volume hospitals and transferring patients to high-volume hospital can achieve the best outcome regarding the prevention of in-hospital mortality.



**Figure 3.** The non-linear relationship between the surgeon experience volume (defined as the sequential number of open surgical procedures for ATAAD performed by the surgeon after January 1, 2005) and in-hospital mortality rate (**A**). The relationship (**B**) and non-linear relationship (**C**) between the duration from the 1st to 25th operations of the surgeon and in-hospital mortality rate. ATAAD, acute type A aortic dissection.

#### Data availability

The datasets generated and analyzed during the current study are not publicly available due to the policy and regulation of the Institutional Review Board of Chang Gung Memorial Hospital, but are available from the corresponding author on reasonable request.

Received: 9 April 2022; Accepted: 22 February 2023 Published online: 03 March 2023

#### References

- 1. Bossone, E., LaBounty, T. M. & Eagle, K. A. Acute aortic syndromes: Diagnosis and management, an update. *Eur. Heart J.* **39**(9), 739–49d. https://doi.org/10.1093/eurheartj/ehx319 (2018).
- Strayer, R. J., Shearer, P. L. & Hermann, L. K. Screening, evaluation, and early management of acute aortic dissection in the ED. Curr. Cardiol. Rev. 8(2), 152–7. https://doi.org/10.2174/157340312801784970 (2012).
- Howard, D. P. et al. Population-based study of incidence and outcome of acute aortic dissection and premorbid risk factor control: 10-year results from the Oxford Vascular Study. Circulation 127(20), 2031–7. https://doi.org/10.1161/circulationaha.112.000483 (2013).
- Landenhed, M. *et al.* Risk profiles for aortic dissection and ruptured or surgically treated aneurysms: A prospective cohort study. J. Am. Heart Assoc. 4(1), e001513. https://doi.org/10.1161/jaha.114.001513 (2015).
- DeMartino, R. R. et al. Population-based assessment of the incidence of aortic dissection, intramural hematoma, and penetrating ulcer, and its associated mortality from 1995 to 2015. Circ. Cardiovasc. Qual. Outcomes 11(8), e004689. https://doi.org/10.1161/ circoutcomes.118.004689 (2018).
- von Kodolitsch, Y., Schwartz, A. G. & Nienaber, C. A. Clinical prediction of acute aortic dissection. Arch. Intern. Med. 160(19), 2977–82. https://doi.org/10.1001/archinte.160.19.2977 (2000).
- Klompas, M. Does this patient have an acute thoracic aortic dissection?. Jama 287(17), 2262–72. https://doi.org/10.1001/jama. 287.17.2262 (2002).
- Mussa, F. F. et al. Acute aortic dissection and intramural hematoma: A systematic review. Jama 316(7), 754–63. https://doi.org/ 10.1001/jama.2016.10026 (2016).
- Pape, L. A. et al. Presentation, diagnosis, and outcomes of acute aortic dissection: 17-year trends from the international registry of acute aortic dissection. J. Am. Coll. Cardiol. 66(4), 350–8. https://doi.org/10.1016/j.jacc.2015.05.029 (2015).
- Evangelista, A. *et al.* Insights from the international registry of acute aortic dissection: A 20-year experience of collaborative clinical research. *Circulation* 137(17), 1846–60. https://doi.org/10.1161/circulationaha.117.031264 (2018).
- Bashir, M. et al. Acute type A aortic dissection in the United Kingdom: Surgeon volume-outcome relation. J. Thorac. Cardiovasc. Surg. 154(2), 398-406.e1. https://doi.org/10.1016/j.jtcvs.2017.02.015 (2017).
- Cheng, Y. T. et al. Long-term outcomes of endovascular and open repair for traumatic thoracic aortic injury. JAMA Netw. Open 2(2), e187861. https://doi.org/10.1001/jamanetworkopen.2018.7861 (2019).

- Trimarchi, S. et al. Contemporary results of surgery in acute type A aortic dissection: The international registry of acute aortic dissection experience. J. Thorac. Cardiovasc. Surg. 129(1), 112–22. https://doi.org/10.1016/j.jtcvs.2004.09.005 (2005).
- Goldstone, A. B. *et al.* Interfacility transfer of medicare beneficiaries with acute type A aortic dissection and regionalization of care in the United States. *Circulation* 140(15), 1239–50. https://doi.org/10.1161/circulationaha.118.038867 (2019).
- Brescia, A. A. *et al.* Volume-outcome relationships in surgical and endovascular repair of aortic dissection. *Ann. Thorac. Surg.* 108(5), 1299–306. https://doi.org/10.1016/j.athoracsur.2019.06.047 (2019).
- Chikwe, J. et al. National outcomes in acute aortic dissection: Influence of surgeon and institutional volume on operative mortality. Ann. Thorac. Surg. 95(5), 1563–9. https://doi.org/10.1016/j.athoracsur.2013.02.039 (2013).
- Tsai, M. S. *et al.* Chang Gung research database: A multi-institutional database consisting of original medical records. *Biomed. J.* 40(5), 263–69. https://doi.org/10.1016/j.bj.2017.08.002 (2017).
- Hsu, M. E. et al. Outcomes of acute aortic dissection surgery in octogenarians. J. Am. Heart Assoc. 9(18), e017147. https://doi.org/ 10.1161/jaha.120.017147 (2020).
- Chen, S. W. et al. Association of family history with incidence and outcomes of aortic dissection. J. Am. Coll. Cardiol. 76(10), 1181–92. https://doi.org/10.1016/j.jacc.2020.07.028 (2020).
- Chen, S. W. et al. Effect of β-blocker therapy on late outcomes after surgical repair of type A aortic dissection. J. Thorac. Cardiovasc. Surg. 159(5), 1694–703.e3. https://doi.org/10.1016/j.jtcvs.2019.05.032 (2020).
- Zhu, Y. *et al.* Type A aortic dissection-experience over 5 decades: JACC historical breakthroughs in perspective. *J. Am. Coll. Cardiol.* 76(14), 1703–13. https://doi.org/10.1016/j.jacc.2020.07.061 (2020).
- Birkmeyer, J. D. et al. Surgeon volume and operative mortality in the United States. N. Engl. J. Med. 349(22), 2117–27. https://doi. org/10.1056/NEJMsa035205 (2003).

#### Acknowledgements

This study was based on data from the CGRD provided by the Chang Gung Memorial Hospital administration. However, the interpretation and conclusions in this paper represent only the authors. The authors thank the Maintenance Project of the Center for Big Data Analytics and Statistics (Grant CLRPG3D0049) at Chang Gung Memorial Hospital for statistical consultation and data analysis. The authors also thank Alfred Hsing-Fen Lin and Bing-Yu Chen for their assistance with the statistical analysis. The authors thank Wallace Academic Editing for assistance in editing this manuscript.

#### Author contributions

(I) Conception and design: B.-C.H., C.-C.W., Y.-T.C., P.-H.C., S.-W.C. (II) Administrative support: F.-C.H., Y.-T.C., K.-S.L. (III) Provision of study materials or patients: A.-H.C., S.-W.C. (IV) Collection and assembly of data: B.-C.H., Y.-T.H., S.-H.C. (V) Data analysis and interpretation: B.-C.H., Y.-T.H., Y.-T.C. (VI) Manuscript writing: All authors (VII) Final approval of manuscript: All authors.

#### Funding

This work was supported by a grant from Chang Gung Memorial Hospital, Taiwan ORPG3M0371, CFRPG3M0011, CMRPG3L0101, CMRPG3L0102, CMRPG3L0103, and BMRPD95(SWC). This work was also supported by the Ministry of Science and Technology grant MOST-110-2314-B-182A-114(SWC).

#### Competing interests

The authors declare no competing interests.

#### Additional information

**Supplementary Information** The online version contains supplementary material available at https://doi.org/ 10.1038/s41598-023-30397-2.

**Correspondence** and requests for materials should be addressed to S.-W.C.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2023